Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Isis
 More »

  • Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
    Isis Pharmaceuticals just earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase II study of ISIS-SMN Rx in infants ...
    5-10-2013
  • Critical Tools for Oligo Characterization
    ... Each method yields more and more information." Product Specifications: Why We Analyze Isis ... According to Daniel Capaldi, Ph.D., vp for analytic and process development at Isis ...
    5-1-2013
  • GEN | Biolinks
    ... Isis Pharmaceuticals Italian Association for the Development of Biotechnology - Assobiotec James Madison University Jamestown Community College Janssen Biotech, Inc. ...
  • Roche and Isis Pharmaceuticals Set Sights on Huntington's
    Roche and Isis Pharmaceuticals have formed an alliance to develop treatments for ... In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's ...
    4-8-2013
  • Mystery Rare Disease Drug Earns Isis $5M from GSK
    Isis Pharmaceuticals received a $5 million milestone payment from GlaxoSmithKline (GSK) toward the development of a drug to treat an undisclosed rare and serious disease. Isis will ...
    2-19-2013
  • Pioneering Antisense Drug Gets FDA Approval
    Isis Pharmaceuticals and Sanofi's Genzyme subsidiary said today they are gearing up for ... with analysts. "This is a seminal day for Isis, and it is a seminal day for the ...
    1-30-2013
  • The New Economics of Orphan Diseases
    ... GSK also has partnered with JCR Pharmaceuticals, Isis Pharmaceuticals, Fondazione Telethon, and Fondazione San Raffaele for gene therapies. Emergent BioSolutions, the only U.S. ...
    1-1-2013
  • People in the News
    Formerly, he was leader of the specialty pharmaceuticals R&D team. Before joining Shire, Dr. Jonas served as evp at Isis Pharmaceuticals. Prior to this, Jeff was CMO and evp at ...
    1-1-2013
  • Antisense Making Sense to Isis Partners
    Yet another firm is tapping Isis for its antisense technology. In the latest deal, ... The agreement includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis is ...
    12-11-2012
  • Isis Gets More Money from Biogen Idec
    Biogen Idec and Isis Pharmaceuticals will work together to discover and develop antisense ... Under terms of the agreement, Isis will receive an up-front payment of $30 million and is ...
    12-10-2012
  • Pfizer Pays Isis $1.25M in Scar Treatment Deal
    Isis Pharmaceuticals will receive a $1.25 million contingent payment from Pfizer, which ... Last year, Isis received $4.4 million for its equity ownership of Excaliard from Pfizer's ...
    11-2-2012
  • Biotech Valuations at trough levels
    ... An $18 million investment was made in Oxford Nanopore, a technology out of the U.K. that utilizes nanopores to measure current flow for rapid sequencing. Isis (ISIS) -Isis has ...
    8-13-2012
  • Clinical Application of miRNAs a Ways Off
    ... Regulus Therapeutics, established by Alnylam and Isis in September 2007, combines the companies' expertise in oligonucleotide chemistry to develop miRNA-targeted drugs. Regulus' ...
    8-1-2012
  • Top Paid Women in Biopharma
    2011 Compensation: $1,403,020 (A$1,337,883) #22. B. Lynne Parshall Director, COO, CFO, Isis Pharmaceuticals 2011 Compensation: $1,434,819 #21. Marcea Bland Lloyd SVP, Chief ...
    7-30-2012
  • Clinical Application of miRNAs Remains a Ways Off
    ... Regulus Therapeutics, established by Alnylam and Isis in September 2007, combines the companies' expertise in oligonucleotide chemistry to develop miRNA-targeted drugs. Regulus' ...
    7-17-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll